Advertisement
U.S. markets closed

GSK plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
42.14-0.05 (-0.12%)
At close: 04:00PM EDT
42.14 0.00 (0.00%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close42.19
Open42.21
Bid42.22 x 1800
Ask42.23 x 2200
Day's Range42.14 - 42.35
52 Week Range33.33 - 43.84
Volume1,327,296
Avg. Volume3,593,916
Market Cap85.513B
Beta (5Y Monthly)0.26
PE Ratio (TTM)13.82
EPS (TTM)3.05
Earnings DateN/A
Forward Dividend & Yield1.47 (3.48%)
Ex-Dividend DateFeb 22, 2024
1y Target Est44.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GSK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GSK plc
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    15 hours agoArgus Research
View more
  • The Wall Street Journal

    Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?

    AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.

  • Bloomberg

    Pfizer Plans to Sell About £2 Billion of Shares in Haleon

    (Bloomberg) -- Pfizer Inc. plans to sell about £2 billion ($2.5 billion) of shares in Haleon Plc, the first step by the UK consumer health company’s biggest shareholder to reduce its 32% stake. Most Read from BloombergApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesPutin Warns Russia Won’t Stop After Predictable Election WinSaudi Wealth Fund Is in Talks to Acquire National AirlineTop Solar Firm Longi Plans Thousands of Job Cuts on GlutChina’s Growth Bump May Dent Urgency for More

  • Business Wire

    Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

    PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer